Unique ID issued by UMIN | UMIN000018654 |
---|---|
Receipt number | R000021592 |
Scientific Title | Randomized comparative trial of vonoprazan and esomeprazole in triple therapy for the eradication of Helicobacter pylori. |
Date of disclosure of the study information | 2015/08/14 |
Last modified on | 2021/10/15 10:59:45 |
Randomized comparative trial of vonoprazan and esomeprazole in triple therapy for the eradication of Helicobacter pylori.
Comparative trial of vonoprazan and esomeprazole for the eradication of Helicobacter pylori (VEHP trial)
Randomized comparative trial of vonoprazan and esomeprazole in triple therapy for the eradication of Helicobacter pylori.
Comparative trial of vonoprazan and esomeprazole for the eradication of Helicobacter pylori (VEHP trial)
Japan |
Chronic gastritis with Helicobacter pylori infection
Gastroenterology |
Others
NO
To evaluate the efficacy and safety of vonoprazan based triple therapy compared with esomeprazole based therapy as first-line eradication therapy for patients with Helicobacter pylori infection.
Safety,Efficacy
Confirmatory
Explanatory
Phase IV
Eradication rate of the first-line therapy assessed by a urea breath test from 6 to 10 weeks after cessation of therapy.
Eradication rate of second-line therapy with vonoprazan in the patients who failed first-line therapy.
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
YES
NO
Institution is considered as a block.
Central registration
2
Treatment
Medicine |
Vonoprazan 40mg, ABPC 1500mg, CAM 400mg, for the first 7days, with all drugs given twice daily
Esomeprazole 40mg, ABPC 1500mg, CAM 400mg, for the first 7 days, with all drugs given twice daily
20 | years-old | <= |
Not applicable |
Male and Female
Patients who received a diagnosis of Helicobacter pylori gastritis by any one method of a rapid urease test, a urea breath test, a blood antibody test, a stool antigen test, and microbial culture.
1. Patients who suggested or received a diagnosis of other infectious diseases.
2. Patients who received a diagnosis of acute gastritis, advanced gastric cancer, gastric MALT lymphoma, and postgastrectomy by endoscopic examination.
3. Patients who have coexisting severe heart disease, liver disease, renal disease, respiratory disease, metabolic disease, and neuromuscular disease.
4. Patients who received any one of lansoprazole, esomeprazole, omeprazole, and vonoprazan within 2 weeks.
5. Patients who have histories of eradication therapy for Helicobacter pylori.
6. Patients who have a past history of allergy for vonoprazan, esomeprazole, amoxicillin, clarithromycin, and metronidazor.
7. Pregnancy.
520
1st name | Hiroyuki |
Middle name | |
Last name | Tamaki |
Takamatsu Redcross Hospital
Gastroenterology
7600075
4-1-3, Ban-cho, Takamatsu , Kagawa
087-831-7101
h-tama@gc4.so-net.ne.jp
1st name | Hiroyuki |
Middle name | |
Last name | Tamaki |
Takamatsu Redcross Hospital
Gastroenterology
7600075
4-1-3, Ban-cho, Takamatsu , Kagawa
087-831-7101
h-tama@gc4.so-net.ne.jp
Takamatsu Redcross Hospital
None
Self funding
Takamatsu Red Cross Hospital
4-1-3, Ban-cho, Takamatsu, Kagawa, Japan
0878317101
tamaki33@gmail.com
NO
高松赤十字病院(香川)、石川クリニック(香川)、関西電力病院(大阪)、なお消化器クリニック(静岡)、天理よろづ相談所病院(奈良)、よしなれクリニック(香川)、なかじまクリニック(兵庫)、京都桂病院(京都)
2015 | Year | 08 | Month | 14 | Day |
Unpublished
No longer recruiting
2015 | Year | 06 | Month | 08 | Day |
2015 | Year | 06 | Month | 08 | Day |
2015 | Year | 08 | Month | 12 | Day |
2021 | Year | 10 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021592
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |